Results 131 to 140 of about 29,446 (242)

Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report [PDF]

open access: yes
Yuzhu Mu, Ting Pan, Lingling Chen Department of Dermatology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, 215000, People’s Republic of ChinaCorrespondence: Lingling Chen, Email chenlingling031 ...
Pan T, Mu Y, Chen L
core   +1 more source

Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1392-1405, August 2026.
This pan‐European study reveals high rates of addiction in patients with chronic skin diseases. Smoking, alcohol, drug use, gambling, and internet addiction were prevalent and associated with quality of life, demographics, and region. The findings support integrating addiction screening into dermatologic care to improve outcomes.
Stefanie Ziehfreund   +73 more
wiley   +1 more source

Role of Autophagy Induced by Pmel17 in the Pathogenesis of Vitiligo [PDF]

open access: yes
Lijun Sun,1,2 Jingying Sun,1,2 Yangmeng Feng,1,2 Longfei Zhu,3 Huijin Li,4 Cuixiang Xu,1,2 Chunyan Guo1,2 1Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, 710068, People’s Republic
Sun L   +6 more
core   +1 more source

Thyroid Functions and Autoantibodies in Vitiligo Patients in Istanbul Medeniyet University Göztepe Education and Research Hospital [PDF]

open access: yes, 2015
Amaç Vitiligo melanositlerin yıkımı ile seyreden depigmentasyon ile karakterize yaygın bir deri hastalığıdır. Etyopatogenezi tam olarak bilinmemekle beraber otoimmün hipotez üzerinde durulmaktadır.
Sadettin Dürüyen   +15 more
core  

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1406-1419, August 2026.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla   +33 more
wiley   +1 more source

Physician burnout or joy: Rediscovering the rewards of a life in medicine,

open access: yesInternational Journal of Women's Dermatology, 2020
Pearl E. Grimes, MD
doaj   +1 more source

Integrative Proteomics and Genomics Identify Novel Biomarkers and Therapeutic Targets in Vitiligo via Mendelian Randomization

open access: yesDermatology and Therapy
Introduction Given that the proteome is a major source of therapeutic targets, we conducted a proteome-wide Mendelian randomization (MR) combined with transcriptome sequencing analysis to identify candidate protein markers and therapeutic targets for ...
Chenjue Yan   +5 more
doaj   +1 more source

Treatment advances in Vitiligo: An Updated Review

open access: yesDermatology Practical & Conceptual
Introduction Vitiligo is a common disorder of depigmentation caused by the progressive destruction of melanocytes that affects the skin, hair, and mucous membranes, clinically presenting as depigmented macules and leukotrichia.
Ishrat Binti Ismail   +2 more
doaj   +1 more source

Challenging White Lesion

open access: yes
Oral Diseases, EarlyView.
Michele Di Benedetto   +5 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy